Figure 2
Effect of mevalonate-derived products on 20 μM zoledronate-induced inhibition of prostatic cell proliferation. At D0, cells were seeded into 96-well plates to obtain 80% confluence at D5 in control wells. At D1, and D3, cells were treated by vehicle or 20 μM zoledronate (ZOL) in the presence or absence of intermediates of the mevalonate pathway (GGOH = geranyl-geraniol; MVA = mevalonate; FOH = farnesol; SQUA = squalene) at the indicated doses. Results are are expressed as the ratio ODtreated cells/ODuntreated of three independent assays each performed six times. Error bars indicate inter-assay mean ± 1 SD. * indicates a significant difference versus ZOL-treated cells (p < 0.01). 
PC-3 
PNT1A 
LNCaP